# Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors

> **NCT04309968** · PHASE1 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 186 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Drug: SYHA1801

## Key facts

- **NCT ID:** NCT04309968
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-07
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2020-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04309968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04309968, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04309968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*